ClinicalTrials.gg
CompletedNCT00043771Updated Jun 24, 2005

Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients

A Phase 2 interventional study of Tolvaptan in Congestive Heart Failure, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tolvaptan in Heart Failure — none open to participants now, none under way, none of them phase 3. Tolvaptan · Heart Failure.

Enrollment
12th of 19
40 · median 60
Started
2002
with 1 other
Phase 2
4 of 19
none open now
Registered
1st of 19
by date
Lead sponsor
5 of 19
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 19 studies testing tolvaptan in Heart Failure, this one is the 12th largest by enrollment, is one of 2 that started in 2002, is one of 4 in phase 2, and was the 1st registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

None of the 19 studies testing tolvaptan in Heart Failure is open now. The open studies under Heart Failure, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing tolvaptan in Heart Failure as a file.
02

Study summary

Patients with congestive heart failure will be assessed for safety and clinical effects of Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days.

03

Conditions studied

  • Congestive Heart Failure

Browse trials for

Keywords

  • CHF
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

History of CHF

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
40 participants

Interventions

06

Study locations

9 sites
  • Central Cardiology Medical Clinic
    Bakersfield, California, United States
  • University of California-San Diego
    San Diego, California, United States
  • University of Miami/Jackson Memorial Hospital
    Miami, Florida, United States
  • Medical Research Institute
    Slidell, Louisiana, United States
  • Androscoggin Cardiology Associates
    Auburn, Maine, United States
  • University of Missouri-Kansas City School of Medicine
    Kansas City, Missouri, United States
  • Saint Louis University
    St. Louis, Missouri, United States
  • Cardiology of Oklahoma
    Tulsa, Oklahoma, United States
  • Medical University of South Carolina
    Charleston, South Carolina, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2002 and a completion of Sep 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2002
First posted
Aug 14, 2002
Start
May 2002
Completion
Sep 2002
Last update
Jun 24, 2005
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00043771
First posted
Aug 14, 2002
Start date
May 2002
Completion
Sep 2002
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2002. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion